Angiogenesis modulation by exogenous antioxidants

Pathogenesis of several serious human diseases is related to oxidative stress and pathological neovascularization. Oxidative stress, the imbalance between production of reactive oxygen species (ROS) and antioxidant mechanisms, disturbs redox homeostasis in a single cell and the organism [ 1 ]. It generates damage of cellular components, disturbances of their biological function and can lead to metabolism dysfunction [ 2 ]. A close relationship between ROS and neovascularization indicates that oxidative stress influences the angiogenesis process, too. Angiogenesis is the process of formation of new blood vessels sprouting from the existing one. Key mediators triggering formation of new vessels (e.g. vascular-epithelial growth factor (VEGF), fibroblast growth factor (FGF), matrix metalloproteinases (MMP), some interleukins (including IL-8), transforming growth factor α (TGF-α), some adhesion molecules e.g. ICAM-1 (CD 54)), as well as hindering this process (e.g. tissue inhibitors of metalloproteinases (TIMP), interferons, TGF-β, IL-10, IL-4 and IL-12, IL-18) show at the same time a respective pro- or anti-angiogenic activity [ 3 , 4 ]. In physiological conditions, angiogenesis influences the menstrual cycle, embryogenesis and wound healing, but its disturbances underlie many serious diseases, called angiogenesis-dependent diseases [ 2 ]. Excessive, pathological neovascularization has been reported e.g. in the case of neoplastic tumors, endometriosis, psoriasis, rheumatoid arthritis (RA), when its too low level is detected in e.g. neurodegenerative diseases, diabetes, hypertension, and ischemic heart disease. At the same time, all these diseases are accompanied by a chronic inflammatory state, and their pathomechanism is usually associated with oxidative stress [ 3 , 4 ]. Antioxidants have been defined as substances that, when present at low concentrations, compared to oxidizable compound (e.g. DNA, lipids, proteins, carbohydrates), significantly delay or prevent substrate oxidation [ 5 , 6 ]. They neutralize free oxygen radicals, including ROS, and their activity, and counteract consequences of oxidative stress. ROS at high doses become deleterious, exhibiting pathophysiological actions and as mentioned above, can lead to oxidative stress. On the contrary, low doses of ROS are beneficial for normal physiological actions. The antioxidant defense system includes both endogenous and exogenous antioxidants. Antioxidant enzymes such superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), heme oxygenase and non-enzymatic, low molecular-weight scavengers (e.g. glutathione (GSH), uric acid, coenzyme Q, lipoic acid, ascorbic acid, tocopherol) belong to the endogenous defense system. The exogenous defense system includes antioxidants that can be grouped depending to their origin as natural (e.g. carotenoids and polyphenols, with the diet being the main source), nature identical (e.g. vitamin C, vitamin E) and synthetic – synthetized by the industry (e.g. N-acetylcysteine) [ 6 ]. The endogenous and exogenous defense system maintains or re-establishes redox homeostasis, such as during the regeneration of vitamin E by glutathione (GSH) or vitamin C to prevent lipid peroxidation processes, which can affect membrane fluidity and damage membrane proteins [ 7 ]. Through reduction of oxidative stress and the influence on neovascularization, antioxidants may modulate progress and results of therapy in those diseases, where such processes play an important role.

A lot of other natural substances with antioxidant properties inhibiting angiogenesis have been described. Echinacea purpurea is one of the components of Reumaherb preparation. Residual components are flowers of queen-of-the-meadow ( Filipendula ulmaria ) and the extract from grapple plant root ( Harpagophytum procumbens ). Until now, Reumaherb was used mainly in the adjuvant treatment of inflammatory and degenerative diseases of joints, e.g. rheumatoid arthritis and pain syndromes of soft tissues of the locomotor system. The preparation shows anti-inflammatory, analgesic, anti-oxidative, immunomodulatory and regeneration-stimulating properties [ 30 ]. As our study indicates, Reumaherb can display anti-angiogenic properties when applied orally at a dose of 1.2 mg per mice. In this research immunological angiogenesis induced by bronchoalveolar cells (BAL) isolated from patients with sarcoidosis and grafted into Balb/C mice skin was diminished [ 41 ] by this preparation. Similar experiments with Reumaherb was performed on mononuclear cells derived from RA patients. Reumaherb applied orally to the mice at daily doses of 1.2 mg per mice diminished angiogenic response of mononuclear cells [ 30 ]. Resveratrol is a polyphenolic compound with antioxidative properties found in grapes, red wine and other fruits. Brakenhielm [ 42 ] demonstrated the inhibitory effect of resveratrol on angiogenesis and inflammation in both in vitro and in vivo models. Resveratrol reduced endothelial cells growth stimulated by FGF-2 and VEGF. It diminished in a dose-dependent manner angiogenesis in a chick chorioallantoic membrane assay [ 42 ]. Besides it inhibited corneal neovascularization induced by VEGF and FGF-2. Antiangiogenic properties of this substance rely on the influence of VEGF signaling. Resveratrol at a dose of 1-2.5 μM exposure of HUVEC cells blocked VEGF mediated migration and tube formation as well as tyrosine phosphorylation of vascular endothelial cadherin and β-catenin. Besides VEGF-induced endogenous Src kinase activation was strongly inhibited by 1 and 2.5 μM of resveratrol [ 42 , 43 ]. Furthermore, resveratrol exerts antiangiogenic action by inhibiting NADPH oxidase (NOX-1) and monocyte chemotactic protein-1 production [ 44 ]. NOX are the main sources of ROS in endothelial cells. NOX regulates angiogenesis through production of VEGF and its receptor VEGR-2, MMPs and transcription factors that contribute to the angiogenesis process (e.g. NF-B, AP-1, STAT 1/3, E2F, CREB, HIF-1) [ 45 , 46 ]. Seong reported that resveratrol suppresses VEGF secretion via inhibition of CXC-chemokine receptor 4 (CXCR4) expression in ARPE-19 cells [ 47 ]. A lot of studies concerned anticancer properties of resveratrol. It inhibited the growth of T241 fibrosarcoma in mice. In this study, resveratrol was administered orally at a concentration of 25 μM [ 42 ]. It was reported that resveratrol and black tea polyphenol combination synergistically diminished mouse skin tumors growth by blocking of MAPKs and p53 [ 48 ]. Resveratrol and 5-fluorouracil inhibited cells growth and angiogenesis in B16 murine melanoma model [ 49 ]. Moreover, resveratrol inhibited oxidative stress based on DNA damages in lymphocytes of patients suffering from AMD, an eye disease caused by excessive pathological neovascularization in retina. Resveratrol at a concentration of 5-50 μmlo/l reduced the DNA lesion in lymphocytes of patients with AMD as compared to healthy controls [ 50 ]. As mentioned above, consumption of drinking tea, rich in EGCG and other polyphenolic compounds, is the most popular beverage worldwide. Cao and Cao studied the angiogenic properties of EGCG. They show that EGCG inhibits proliferation of endothelial cells from bovine capillaries in a dose-dependent manner. Angiogenesis was also inhibited by EGCG in chick chorioallantoic membrane assay [ 51 ]. Besides green tea consumption (EGCG in a concentration similar to levels after drinking 2-3 cups of tea) inhibited angiogenesis in a model of corneal neovascularization in mice stimulated by VEGF [ 51 ]. It was also demonstrated that EGCG diminish angiogenesis through suppression of IL-8 production by human microvascular endothelial cells [ 52 ]. Inflammatory angiogenesis was also reduced by EGCG in an in vivo study [ 53 ]. Angiogenesis inhibition by EGCG was related to downregulation of MMP activity [ 54 ], removing ROS [ 55 ] and decreasing VEGF induction in human colon carcinoma [ 56 ]. A study of Junk et al . demonstrated that treatment with EGCG (1.5 mg/day/mouse for 20 days) athymic BALB/C nude mice inoculated subcutaneously with human colon cancer cells diminished the number of tumor microvessels, cell proliferation and increase in apoptosis of tumoral and endothelial cells [ 56 ]. EGCG inhibited transcription factor AP-1, binding to DNA. AP-1 upregulates MMP-1 gene and plays an important role in metastatic behavior of cancer cells [ 57 ].

Disturbances of angiogenesis might have serious medical consequences. An abnormally high angiogenesis level is characteristic for cancer, one of the most dangerous and still incurable diseases. In turn, too low angiogenesis can be observed in diabetes mellitus or ischemic heart disease. Pathogenesis of these and many others civilization diseases include also oxidative stress. Co-operation of the endogenous and exogenous defense system maintain redox homeostasis and is essential for health. In this review, the influence of exogenous antioxidants on various parameters of neovascularization was described. Most presented synthetic antioxidants exert an inhibitory effect on neovascularization. A similar effect is exhibited also by some natural origin antioxidants (e.g. resveratrol, EGCG), which suggests that their application in therapy might normalize excessive angiogenesis. Although, the use of these antioxidants in the treatment of diseases associated with a too low angiogenesis level is risky as it may bring adverse results. Some natural origin antioxidants e.g. purple coneflower and preparation consisting natural antioxidants such Padma 28 increase a too low baseline level of angiogenesis and decreases a too high level. These preparations exert a regulatory effect on angiogenesis and their action may normalize the disturbed angiogenesis process. These natural origin antioxidants can be used in the case of diseases associated with too low or too high angiogenesis.

Majority of exogenous antioxidants are derived from plants, fungi, microorganisms or animals so they are called natural. Most available preparations with antioxidant properties belong to this group. Purple coneflower ( Echinacea purpurea ) has proven anti-oxidative, anti-inflammatory and immunostimulating properties. It is used as an adjunctive treatment (in Germany it is registered as a drug) in diseases associated with immunity disturbances, particularly often in viral, bacterial and fungal infections of the respiratory tract [ 30 ]. An aqueous-alcoholic extract of purple coneflower in the form of tablets (IMMUNAL forte, Lek, Slovenia) administered to healthy volunteers, stimulated angiogenic activity in their mononuclear leukocytes (MNC) in the test of cutaneous angiogenesis (LIA) in mice [ 31 ]. IMMUNAL forte was administered to 6 healthy volunteers in the form of 1 tablet (80 mg) and 8 healthy volunteers in the form of 2 tablets (160 mg) daily for 7 days. The control group included healthy donors (8 people) receiving 1 placebo tablet daily. Angiogenic activity of peripheral blood leukocytes of evaluated persons before and after 7 days of treatment with purple coneflower was strongly stimulated by both evaluated doses of the preparation. These results constitute a confirmation of the previous studies on the preparation (IMMUNAL in the form of juice) with participation of healthy volunteers, which have proven an effect stimulating cellular immunity [ 32 ]. Moreover, E. purpurea extract was present to enhance immunity in mice [ 33 ]. An angiostimulatory effect of E. purpurea was achieved when this herb was administered to healthy volunteers’ organism, with a physiological (normal) level of immune function and angiogenesis. As mentioned above, the excessive angiogenic response occurs in some diseases such as cancer, sarcoidosis and rheumatoid arthritis [ 2 , 30 ]. E. purpurea is able to diminish abnormally high angiogenesis and restore it to the physiological level, so it acts as a regulator of the disturbed function. It was proved that E. purpurea extract lowered neovascular reaction induced in the mouse skin by human cancer cells. Besides angiogenic response induced in the mouse skin by syngeneic L1-sarcoma cells as well as VEGF concentration in L1 sarcoma tissue [ 33 , 34 ] was also reduced by this herb demonstrate that the drug may normalize the angiogenesis process (it increases a too low baseline level of angiogenesis and decreases a too high level). PADMA 28, preparation produced by the Swiss company, PADMA AG, consists of 20 natural ingredients (usually medicinal herbs) and originates from traditional Tibetan medicine. It is suggested that the preparation exhibits strong angioprotective, antioxidative, immunostimulating, anti-inflammatory, anti-peroxidative, cytoprotective and anabolic activity. According to the producer, chronic illnesses with inflammatory, atherosclerotic (including pathology of the peripheral and central vascular system) and degenerative background, as well as infectious diseases (in particular chronic, recurring infections of the respiratory tract) constitute the indication to use this supplement [ 35 ]. In our research [ 36 ], PADMA 28 was administered to mice per os , at a dose of 5.8 mg and 0.085 mg/day/mouse, in 40 μl of water for 7 days, while animals from control groups received 40 μl of water. Then, mice were bled under anesthesia, sacrificed, and spleens were harvested. Isolated splenocytes were implanted intradermally into recipient mice (Balb/c x C3H). After 3 days, new blood vessels induced by angiogenic factors released by implanted splenocytes (LIA test) were calculated. Studies presented in this paper prove that both doses of PADMA 28 preparation cause a statistically significant, dose-dependent increase in the number of new blood vessels. Moreover, the number of peripheral blood granulocytes and lymphocytes after 7 days of feeding with a lower dose of PADMA 28, increased significantly. At the same time, metabolic activity of peripheral blood granulocytes, determined by the intensity of their chemiluminescence, decreased after 7 days of feeding with a higher dose of preparation. This suggests that the lower dose, which also stimulated angiogenesis, may be safer in therapy. Results of this paper suggest that PADMA 28 preparation may be used in the case of diseases associated with disturbed angiogenesis, e.g. Alzheimer disease, diabetes, atherosclerosis, arterial hypertension, ischemic heart disease, and stroke [ 37 ]. Our earlier studies on PADMA 28 preparation demonstrate that the drug may normalize the angiogenesis process (it increases a too low baseline level of angiogenesis and decreases a too high level). Antiangiogenic activity of PADMA 28 has been demonstrated e.g. on human renal cancer cells [ 38 ]. Padma 28 was also reported to inhibit migration of cancer prostate cells [ 39 ]. Wang et al . [ 40 ] described antiangiogenic activity of this preparation by suppressing AKT/GSK-3β pathways in an in vitro and in vivo angiogenesis assay. Thus, this supplement may be used in the diseases with a high level of angiogenesis, too.